4D Molecular Therapeutics

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru

Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b

Two San Francisco Bay-area biotechs – Adverum Biotechnologies, Inc. and 4D Molecular Therapeutics Inc. – presented updated Phase II readouts on 17 July for their gene therapy candidates for wet ag